Victrex (VCT) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
11 May, 2026Executive summary
Revenue increased 1% year-over-year to £147.1m, driven by 6% volume growth, with a weak Q1 offset by a strong Q2.
Underlying profit before tax (PBT) fell 18% to £19.0m, impacted by adverse mix, pricing pressure, and currency headwinds.
Gross margin declined to 41.7%, down 240bps, due to price pressure, mix, and currency.
A non-cash impairment of £60.6m was recorded for the China plant, reflecting operational challenges and lower-than-expected capacity.
Profit Improvement Plan underway, including a 10% global headcount reduction and new decentralized structure, targeting £10m annualised cost savings by FY 2027.
Financial highlights
Revenue: £147.1m (+1% year-over-year, +2% constant currency); group sales volume up 6% to 2,137 tonnes.
Gross profit: £61.3m, down 5% year-over-year; gross margin: 41.7% (down from 44.1%).
Underlying PBT: £19m (down 18% year-over-year); underlying EPS: 17.2p (down 24%).
Free cash flow: £22m, stable year-over-year; operating cash conversion at 109%.
Net debt: £45.4m (0.65x net debt/EBITDA), supported by new term loan and continued use of RCF.
Outlook and guidance
FY 2026 underlying PBT expected between £42m–£44m.
Full-year gross margin expected slightly below prior year (45.3%), with H2 improvement anticipated.
Exceptional items for FY 2026 anticipated at £75m–£85m, mainly from China impairment.
CapEx to remain below 8–10% of revenues; H2 2026 to benefit from early cost savings.
Capital Markets Day scheduled for September to detail strategy and medium-term ambitions.
Latest events from Victrex
- Net zero by 2050, 53% revenue from sustainable products, and 40% female leadership achieved.VCT
ESG Presentation18 Feb 2026 - Q1 2026 volumes and revenue declined, but full-year guidance and cost-saving plans remain on track.VCT
Q1 2026 TU6 Feb 2026 - Q3 volumes up 20% year-over-year, but Medical destocking continues to weigh on profit outlook.VCT
Q3 2024 TU3 Feb 2026 - Volumes up 4%, revenue down 5%, but margin and PBT growth targeted for FY 2025.VCT
H2 202412 Jan 2026 - 12% volume growth, profit down 21%, £10m savings plan, stable outlook and dividends.VCT
H2 20252 Dec 2025 - 16% volume growth and strong cashflow offset by FX and China ramp-up margin pressure.VCT
H1 202520 Nov 2025 - Q3 volume up 8% but revenue down 3% as medical spine weakness and currency headwinds persist.VCT
Q3 2025 TU8 Jul 2025 - Q1 revenue and volume up; full-year outlook steady as mega-programmes and cost controls drive growth.VCT
Trading Update6 Jun 2025